The role of angiogenesis in prostate development and the pathogenesis of prostate cancer
- PMID: 12599013
- DOI: 10.1007/s00240-002-0287-9
The role of angiogenesis in prostate development and the pathogenesis of prostate cancer
Abstract
New vessel formation, a highly-regulated, active process commencing in the embryo and evident notably during the pubertal growth spurt, is essential for normal prostate development. Reactivation of this process in response to physiological stimuli, particularly hypoxia in mature tissues, occurs with new vessels forming principally from stromal components. Although angiogenesis is complex, putatively involving a multitude of angiogenic factors and inhibitors, there is powerful evidence of the importance of the VEGF system in the development of both the normal prostate and prostate cancer. Recent advances include an understanding of how castration acts through the VEGF system to inhibit angiogenesis. Stromal-endothelial and epithelial-endothelial interactions are just beginning to be investigated. A better understanding of how physiological angiogenesis is controlled should help to provide further insights into the mechanism of disregulated angiogenesis in tumours. Ultimately, new antiangiogenic agents are likely to find a role in the management of patients with prostate cancer.
Similar articles
-
Angiogenesis and the tumour hypoxia response in prostate cancer: a review.Int J Surg. 2005;3(1):61-7. doi: 10.1016/j.ijsu.2005.03.013. Int J Surg. 2005. PMID: 17462260
-
Expression of vascular endothelial growth factor (VEGF) and VEGF receptors in tumor angiogenesis and malignancies.Integr Cancer Ther. 2005 Dec;4(4):315-21. doi: 10.1177/1534735405282557. Integr Cancer Ther. 2005. PMID: 16282508 Review.
-
Role of the vascular endothelial growth factor isoforms in retinal angiogenesis and DiGeorge syndrome.Verh K Acad Geneeskd Belg. 2005;67(4):229-76. Verh K Acad Geneeskd Belg. 2005. PMID: 16334858 Review.
-
Effects of androgen suppression and radiation on prostate cancer suggest a role for angiogenesis blockade.Prostate Cancer Prostatic Dis. 2005;8(2):127-32. doi: 10.1038/sj.pcan.4500779. Prostate Cancer Prostatic Dis. 2005. PMID: 15643450 Review.
-
Suppression of VEGF-mediated autocrine and paracrine interactions between prostate cancer cells and vascular endothelial cells by soy isoflavones.J Nutr Biochem. 2007 Jun;18(6):408-17. doi: 10.1016/j.jnutbio.2006.08.006. Epub 2006 Dec 4. J Nutr Biochem. 2007. PMID: 17142033
Cited by
-
Cytokines and Chemokines as Mediators of Prostate Cancer Metastasis.Int J Mol Sci. 2020 Jun 23;21(12):4449. doi: 10.3390/ijms21124449. Int J Mol Sci. 2020. PMID: 32585812 Free PMC article. Review.
-
Molecular Targeted Therapies in Metastatic Prostate Cancer: Recent Advances and Future Challenges.Cancers (Basel). 2023 May 23;15(11):2885. doi: 10.3390/cancers15112885. Cancers (Basel). 2023. PMID: 37296848 Free PMC article. Review.
-
VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.Br J Cancer. 2013 Aug 20;109(4):957-64. doi: 10.1038/bjc.2013.398. Epub 2013 Jul 16. Br J Cancer. 2013. PMID: 23860526 Free PMC article.
-
4-Acetylantroquinonol B Suppresses Prostate Cancer Growth and Angiogenesis via a VEGF/PI3K/ERK/mTOR-Dependent Signaling Pathway in Subcutaneous Xenograft and In Vivo Angiogenesis Models.Int J Mol Sci. 2022 Jan 27;23(3):1446. doi: 10.3390/ijms23031446. Int J Mol Sci. 2022. PMID: 35163369 Free PMC article.
-
Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.Clin Cancer Res. 2008 Dec 1;14(23):7773-80. doi: 10.1158/1078-0432.CCR-08-1309. Clin Cancer Res. 2008. PMID: 19047104 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical